Effect of functional group polarity on the antimalarial activity of spiro and dispiro-1,2,4-trioxolanes

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 18, 2006, Pages 6368-6382

  Dong, Yuxiang ^a   Tang, Yuanqing ^a   Chollet, Jacques ^b   Matile, Hugues ^c   Wittlin, Sergio ^b   Charman, Susan A ^d   Charman, William N ^d   Tomas, Josefina Santo ^b   Scheurer, Christian ^b   Snyder, Christopher ^b   Scorneaux, Bernard ^b   Bajpai, Saroj ^a   Alexander, Scott A ^a   Wang, Xiaofang ^a   Padmanilayam, Maniyan ^a   Cheruku, Srinivasa R ^a   Brun, Reto ^b   Vennerstrom, Jonathan L ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d MONASH UNIVERSITY   (Australia)

Author keywords

1,2,4 Trioxolane; Antimalarial; Artemisinin; Secondary ozonide

Indexed keywords

[ADAMANTANE 2 SPIRO 3' (1',2',4' TRIOXA)SPIRO[4.5]DECAN 8' YL]METHYLSODIUM SULFATE; ACID; ADAMANTANE 2 SPIRO 3' (1',2',4' TRIOXA)SPIRO[4.5]DECAN 8' ONE PHENYLSEMICARBAZONE; ADAMANTANE 2 SPIRO 3' (1',2',4' TRIOXA)SPIRO[4.5]DECAN 8' ONE PYRIDINOACETYLHYDRAZONE CHLORIDE; ADAMANTANE 2 SPIRO 3' (1',2',4' TRIOXA)SPIRO[4.5]DECAN 8' ONE TOSYLHYDRAZONE; ADAMANTANE 2 SPIRO 3' (1',2',4' TRIOXA)SPIRO[4.5]DECANE 8' METHYLIMIDAZOLE 1 CARBOXYLATE; ADAMANTANE 2 SPIRO 3' (1',2',4' TRIOXA)SPIRO[4.5]DECANE AMIDINOHYDRAZONE; ADAMANTANE 2 SPIRO 3' (11' METHYLENE) 1',2',4',9',13' PENTAOXADISPIRO[4.2. 5.2]PENTADECANE; ADAMANTANE 2 SPIRO 3' (11' OXO) 1',2',4',9',13' PENTAOXADISPIRO[4.2.5.2] PENTADECANE; ADAMANTANE 2 SPIRO 3' (11',11' DICARBOXY) 1',2',4',9',13' PENTAOXADISPIRO[4.2.5.2]PENTADECANE; ADAMANTANE 2 SPIRO 3' (11',12' BENZO) 1',2',4',9',14' PENTAOXADISPIRO[4.2. 5.2]PENTADECANE; ADAMANTANE 2 SPIRO 3' (8' BENZYLOXYIMINO) 1',2',4' TRIOXASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' (8' CARBOXYMETHOXYIMINO) 1',2',4' TRIOXASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' (8' HYDROXY) 8' (2 PYRIDINYLMETHYL) 1',2',4' TRIOXYASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' (8' HYDROXY) 8' (2 THIAZOLYL) 1',2',4' TRIOXYASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' (8' HYDROXYIMINO) 1',2',4' TRIOXASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' (8' METHOXYIMINO) 1',2',4' TRIOXASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' [11',11' BIS(HYDROXYMETHYL)] 1',2',4',9',13' PENTAOXADISPIRO[4.2.5.2]PENTADECANE; ADAMANTANE 2 SPIRO 3' [8' (4' FLUOROPHENYL)] 8' HYDROXY 1',2',4' TRIOXYASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' [8' [(2' PYRIMIDINYLOXY)METHYL]] 1',2',4' TRIOXASPIRO[4.5]DECANE MESYLATE; ADAMANTANE 2 SPIRO 3' [8' [(4 CARBOXYPHENOXY)METHYL]] 1',2',4' TRIOXASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' [8' [(4' PYRIDINYLOXY)METHYL]] 1',2',4' TRIOXASPIRO[4.5]DECANE MESYLATE; ADAMANTANE 2 SPIRO 3' [8' [(HYDROXYAMINO)CARBONYL]] 1',2',4' TRIOXASPIRO[4.5]DECANE; ADAMANTANE 2 SPIRO 3' [8' [[(2' HYDROXYETHYL)AMINO]CARBONYL]] 1',2',4' TRIOXASPIRO[4.5]DECANE; BASE; DISPIRO 1,2,4 TRIOXOLANE; FUNCTIONAL GROUP; PEROXIDE; SPIRO 1,2,4 TRIOXOLANE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG ACTIVITY; LIPOPHILICITY; PHYSICAL CHEMISTRY;

ANTIMALARIALS; HETEROCYCLIC COMPOUNDS; MOLECULAR CONFORMATION; PARASITIC SENSITIVITY TESTS; SPIRO COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33747103049     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.05.041     Document Type: Article

References (34)

1. White N.J. Antimicrob. Agents Chemother. 41 (1997) 1413-1422
2. Ridley R.G. Nature 415 (2002) 686-693
3. O'Neill P.M., and Posner G.H. J. Med. Chem. 47 (2004) 2945-2964
4. Tang Y., Dong Y., and Vennerstrom J.L. Med. Res. Rev. 24 (2004) 425-448
5. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 23 (1997) 3-26
6. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., and Kopple K.D. J. Med. Chem. 45 (2002) 2615-2623
7. Wenlock M.C., Austin R.P., Barton P., Davis A.M., and Leeson P.D. J. Med. Chem. 46 (2003) 1250-1256
8. van de Waterbeemd H., Smith D.A., Beaumont K., and Walker D.K. J. Med. Chem. 44 (2001) 1313-1333
9. Smith D., Jones B.C., and Walker D.K. Med. Res. Rev. 16 (1996) 243-266
10. Dong Y., Chollet J., Matile H., Charman S.A., Chiu F.C.K., Charman W.N., Scorneaux B., Urwyler H., Santo Tomas J., Scheurer C., Snyder C., Dorn A., Wang X., Karle J.M., Tang Y., Wittlin S., Brun R., and Vennerstrom J.L. J. Med. Chem. 48 (2005) 4953-4961
11. Lin A.-J., Klayman D.L., and Milhous W.K. J. Med. Chem. 30 (1987) 2147-2150
12. Griesbaum K., Liu X., Kassiaris A., and Scherer M. Libigs Ann./Recueil (1997) 1381-1390
13. Griesbaum K. Trends Org. Chem. 6 (1997) 145-168
14. Tang Y., Dong Y., Karle J.M., DiTusa C.A., and Vennerstrom J.L. J. Org. Chem. 69 (2004) 6470-6473
15. Trioxolane ester precursors were obtained in 25-63% yields.
16. Brown H.C., and Narasimhan S. J. Org. Chem. 47 (1982) 1604-1606
17. Tian H.-Y., Li H.-J., Chen Y.-J., Wang D., and Li C.-J. Ind. Eng. Chem. Res. 41 (2002) 4523-4527
18. Tang Y., Dong Y., and Vennerstrom J.L. Synthesis (2004) 2540-2544
19. Palm K., Stenberg P., Luthman K., and Artursson P. Pharm. Res. 14 (1997) 568-571
20. Lombardo F., Shalaeva M.Y., Tupper K.A., Gao F., and Abraham M.H. J. Med. Chem. 43 (2000) 2922-2928
21. Using rat liver microsomes, both 1 and 10 had predicted hepatic extraction ratio (ER) values of >0.9. The metabolic stabilities of 29 and 30 were not investigated.
22. The monocarboxylic acid was similarly inactive.
23. Activity is defined as percent reduction in parasitemia on day 3 post-infection compared to an untreated control group. For example, a compound with an activity of 99.99% is 10-fold more active than one with an activity of 99.90% and 100-fold more active than one with an activity of 99.0%.
24. Vennerstrom, J. L.; Dong, Y.; Chollet, J.; Matile, H.; Padmanilayam, M.; Tang, Y.; Charman, W. N. U.S. Patent 6,906,205, 2005.
25. Yang D., Yip Y.-C., Jiao G.-S., and Wong M.-K. J. Org. Chem. 63 (1998) 8952-8956
26. Taylor E.C., and Hu B. Heterocycles 43 (1996) 323-338
27. Dong Y., and Vennerstrom J.L. J. Org. Chem. 63 (1998) 8582-8585
28. Bauer, F.; Neumann, M. U.S. Patent 5,932,747, 1999.
29. Lednicer D., Emmert D.E., Lahti R., and Rudzik A.D. J. Med. Chem. 15 (1972) 1235-1238
30. Lednicer D., Emmert D.E., Lahti R., and Rudzik A.D. J. Med. Chem. 15 (1972) 1239-1243
31. Bovy, P. R.; Cecchi, R.; Courtemanche, G.; Oliva, A.; Viviani, N.; Croci, T. WO 2002044139, 2002; PCT Int. Appl.
32. Meyers A.I., Temple D.L., Haidukewych D., and Mihelich E.D. J. Org. Chem. 39 (1974) 2787-2793
33. Desjardins R.E., Canfield C.J., Haynes J.D., and Chulay J.D. Antimicrob. Agents Chemother. 16 (1979) 710-718
34. Ridley R.G., Matile H., Jaquet C., Dorn A., Hofheinz W., Leupin W., Masciadri R., Theil F.P., Richter W.F., Girometta M.A., Guenzi A., Urwyler H., Gocke E., Potthast J.M., Csato M., Thomas A., and Peters W. Antimicrob. Agents Chemother. 41 (1997) 677-686